At Neuroservices Alliance, we take pride in supporting groundbreaking research in CNS and pain drug discovery. In a recent scientific publication by Latigo Therapeutics, our team provided dorsal root ganglia (DRG) from cyno, dogs, and mice for electrophysiological recordings, enabling the evaluation of LTGO33, a promising non-opioid pain therapeutic targeting voltage-gated sodium channels (NaVs).
With chronic pain affecting over 100 million Americans and current treatments facing challenges such as limited efficacy, dependence risks, and poor tolerability, the development of novel pain therapeutics is more critical than ever. Our contribution to this study reinforces Neuroservices Alliance as a trusted partner for electrophysiology recordings, helping advance innovative treatments for pain disorders.
Click below to download the scientific publication by Latigo Biotherapeutics
Latigo Biotherapeutics Scientific Paper
